ALPMY (Astellas Pharma) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALPMY Astellas Pharma Inc ALPMY
84 GF Score
Price $14.90
GF Value $14.20
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Astellas Pharma Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

ALPMY
84GF Score
Astellas Pharma Inc ALPMY
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Astellas Pharma (ALPMY) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued. The current stock price of $14.90 is trading 4.9% above its estimated GF Value™ of $14.20. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMY:

  • Dividend-Payout-to-FFO:
  • GF Value™: $14.20 vs. price of $14.90 (4.9% above fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the ALPMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
84GF Score

Get the complete analysis for ALPMY

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.90
Price
$14.20
GF Value